Endocrine Abstracts

Introduction: Primary bilateral macronodular adrenal hyperplasia (PBMAH) is an uncommon cause (<1%) of endogenous Cushing’s syndrome (CS). Recently, due to increased number of incidental imaging findings of PBMAH, the clinical expression of the disease has changed in favor of oligosymptomatic or subclinical cases, compared to those with clinically manifest CS, or rarely with secretion of mineralocorticoids, or sex steroids.Case report: A 51-yea...

IntroductionLung Neuroendocrine tumors (NETs) range in aggressiveness from low-grade typical carcinoid (TC) and intermediate-grade atypical carcinoid (AC) to the high-grade large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). TC have excellent prognosis post-surgery and European Neuroendocrine Tumor Society (ENETS) recommands no adjuvant therapy for these well diferentiated tumors.Case report<p clas...

Introduction: We describe the case of a 68-year-old patient, having two MEN1-associated tumors that are not part of the classical triad, with a penetrance of only 40%, and 2%, according to the medical literature. Furthermore, she developed a persistent hyperkalemia after the unilateral adrenalectomy, which is rare and often missed.Case report: In 2011, following a non-specific symptomatology (dry cough, fatigue), a bilobectomy was performed (medium and r...

Background and Aims: GH receptor antagonist (Pegvisomant –PEG) has been shown to obtain IGF1 normalization in 60–90% of patients with acromegaly in clinical trials. The aim of the study is to evaluate real life response and side effects of PEG treatment in monotherapy versus combined with somatostatin analogues and/or cabergoline in patients with somatostatin analogues resistant acromegaly.Methods: We included 40 patients (22F/18 M) cons...

Graves’ disease is an autoimmune thyroid disease which, untreated, carries a significant morbidity risk. Treatment options for Graves’s disease have changed over the decades.AimsTo evaluate the outcome and risk factors for relapses of patients with Graves’s disease treated with antithyroid drugs for at least 2 years.MethodsA retrospective, analytic study on 360 consecutiv...